The authors acknowledge support from the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South London at King’s College Hospital NHS Foundation Trust, and the NIHR Biomedical Research Centre, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, UK.

The study team would like to acknowledge the support of the study steering group and contributors to the report, drawn from the board of SAFE and from the Stroke Association in the UK. We would like to thank the clinicians, researchers and stroke support organisation representatives across EU and SAFE member countries who took the time to respond to our questions. We would also like to thank Professor Anthony Rudd, National Clinical Director for Stroke with NHS England, for his comments on a draft of the Recommendations.

This research and report have been sponsored by Amgen, Bayer, Boehringer Ingelheim, Daiichi- Sankyo, Ipsen, Merz and the Bristol-Myers Squibb and Pfizer Alliance through an educational non-restricted grant. Without their generosity we would not have been able to produce such an important and timely piece of research. They had no influence on the research priorities or editorial content of this report.